Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects with HAE Type I or II who either have participated in a previous BCX7353 study or, in selected countries, in the opinion of the Investigator are expected to derive benefit from an oral treatment for the prevention of angioedema attacks.~* Access to appropriate medication for treatment of acute attacks~* Acceptable effective contraception~* Written informed consent~Key Exclusion Criteria:~* Pregnancy or breast-feeding~* Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study~* Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study~* Discontinuation of study drug due to a hypersensitivity reaction BCX7353 in a prior study~* Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology~* Unacceptable noncompliance in a previous BCX7353 study (if applicable) as assessed by the Sponsor or Investigator~* Investigational drug exposure, other than BCX7353, within 30 days prior to the screening visit (or baseline if no screening visit)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BCX7353 150 mg once daily (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).